Guggenheim Raises ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $86.00

ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) had its price objective boosted by Guggenheim from $84.00 to $86.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock. Other equities research analysts also recently issued reports about the stock. Leerink Partners started coverage on shares […]

Leave a Reply

Your email address will not be published.

Previous post AeroVironment’s (AVAV) Outperform Rating Reiterated at William Blair
Next post Amgen (NASDAQ:AMGN) Price Target Raised to $294.00 at Bank of America